CNTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Centessa Pharmaceuticals (CNTA) is not a strong buy for a beginner investor with a long-term strategy at this time. While the stock has some positive catalysts, such as bullish technical indicators and favorable analyst ratings, significant insider selling, Commodore Capital's divestment, and the lack of late-stage efficacy data for its lead asset ORX750 present notable risks. Additionally, the company's financials show ongoing losses with no revenue growth, which may not align with a beginner investor's risk tolerance.
The technical indicators are moderately bullish. The MACD is positive and expanding, indicating upward momentum. The RSI is neutral at 76.29, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 27.065 and 28.135, while support levels are at 23.605 and 22.535.
Analysts have issued favorable ratings, with price targets ranging from $33 to $62, citing high conviction in ORX750 and potential acquisition interest.
Hedge funds are increasing their positions, with a 325.14% increase in buying over the last quarter.
The stock has shown a 53.4% rise over the past year.
Insiders are selling heavily, with a 3778.14% increase in selling activity over the last month.
Commodore Capital sold a significant stake, indicating a cautious outlook.
ORX750 has not yet demonstrated efficacy in late-stage studies, posing a risk to the company's future growth.
The company has no revenue and continues to report significant losses.
In Q3 2025, the company reported no revenue growth (0% YoY). Net income improved but remained negative at -$54.89 million (+28.96% YoY). EPS also improved to -0.41 (+10.81% YoY), and gross margin remained at 100%.
Analysts are generally bullish on CNTA, with multiple Buy and Outperform ratings. Recent price target increases range from $33 to $62, driven by confidence in ORX750 and the company's potential as an acquisition target. However, these ratings are contingent on future data readouts and commercialization success.
